Inflammation and Cancer: What Can We Therapeutically Expect from Checkpoint Inhibitors?

Mischinger, Johannes; Comperat, Eva; Schwentner, Christian; Stenzl, Arnulf; Gakis, Georgios

dc.contributor.author	Mischinger, Johannes
dc.contributor.author	Schwentner, Christian
dc.contributor.author	Stenzl, Arnulf
dc.contributor.author	Gakis, Georgios
dc.date.accessioned	2016-03-03T14:17:19Z
dc.date.available	2016-03-03T14:17:19Z
dc.date.issued	2015
dc.identifier.issn	1527-2737
dc.identifier.uri	http://hdl.handle.net/10900/68697
dc.language.iso	en	en
dc.publisher	Springer	de_DE
dc.relation.uri	http://dx.doi.org/10.1007/s11934-015-0532-8
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject.ddc	610	de_DE
dc.title	Inflammation and Cancer: What Can We Therapeutically Expect from Checkpoint Inhibitors?	de_DE
dc.type	Article	de_DE
utue.quellen.id	20151209042647_00831
utue.personen.roh	Mischinger, Johannes
utue.personen.roh	Comperat, Eva
utue.personen.roh	Schwentner, Christian
utue.personen.roh	Stenzl, Arnulf
utue.personen.roh	Gakis, Georgios
dcterms.isPartOf.ZSTitelID	Current Urology Reports	de_DE
dcterms.isPartOf.ZS-Issue	Article 59	de_DE
dcterms.isPartOf.ZS-Volume	16	de_DE
utue.fakultaet	04 Medizinische Fakultät